sc-no-longer-accepting-cases

 

 

 

 

 

Were you injured by a blood clot caused by Beyaz birth control pills? If so, Schmidt & Clark, LLP may be able to help you file a Beyaz lawsuit. The manufacturer of Beyaz, Bayer HealthCare, has already paid billions of dollars to settle thousands of lawsuits involving their drospirenone-containing contraceptives, and the litigation is still growing.

UPDATE: Bayer Pays $1.4 Billion in Birth Control Lawsuit Settlements

Bayer is facing over 11,000 lawsuits involving their birth control pills, including Yaz, Yasmin, and Beyaz. These lawsuits are centralized in a federal Multi-District Litigation (MDL No. 2100) in the U.S. District Court for the Southern District of Illinois: In re: Yasmin and YAZ (Drospirenone) Marketing, Sales Practices and Products Liability Litigation.

As of October 2013, Bayer has paid $1.4 billion in settlements for more than 7,000 plaintiffs who developed venous blood clot complications (pulmonary embolism, deep vein thrombosis, etc.), for an average payment of $200,000 per plaintiff — with some women receiving significantly more for severe injuries, disability, or loss of a loved one. Bayer has also set aside $24 million to settle lawsuits involving gallbladder disease.

What is Beyaz?

Beyaz is an oral contraceptive that is essentially the same as Yaz, except with an additional folate B-vitamin to reduce the risk of neural tube defects (such as spina bifida) in case pregnancy occurs. Beyaz contains the following active ingredients:

  • Estrogen — ethinyl estradiol, 0.02-mg
  • Progestin — drospirenone, 3-mg
  • Folic acid — levomefolate calcium, 0.451-mg

Beyaz Blood Clots

The controversial ingredient in Beyaz is drospirenone (DRSP), a new synthetic version of the female sex hormone progestin. Unfortunately, drospirenone is associated with a higher risk of blood clots than older generations of progestin, such as levonorgestrel. In some studies, this risk is estimated to be three times higher for Beyaz than non-drospirenone birth control pills.

FDA Safety Warning for Beyaz and Blood Clots

The U.S. Food and Drug Administration (FDA) has published several warnings about drospirenone, in response to numerous studies linking Beyaz and blood clots. In September 2011, the FDA completed a study of more than 800,000 women on birth control. They found that women on drospirenone were at least 50% more likely to develop blood clots, which translates to approximately 10 cases per 10,000 women. Although the numerical risk is small, blood clots can be deadly, and drospirenone is no more effective at preventing pregnancy than other progestins.

Warning Letters for “Misleading” Advertisements

The FDA also issued three warning letters to Bayer in 2003, 2008, and 2009 for “misleading” women about side effects of Yaz and Yasmin and “failing to provide any risk information.” As a result, millions of women were exposed to an increased risk of blood clots, and thousands were injured by Beyaz. Many women have filed lawsuits, claiming they never would have taken Beyaz if they were properly warned about the risk of blood clots.

Beyaz Side Effects

  • Blood clots
  • Venous thromboembolism
  • Heart attack
  • Stroke
  • Pulmonary Embolism (PE)
  • Deep Vein Thrombosis (DVT)
  • Gallstones
  • Gallbladder disease
  • Organ damage (blindness, brain damage, etc.)
  • And more

FREE Confidential Case Evaluation

To contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 588-0600.

*
*
*